Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.
Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.
Status check updated to Melanotan II in Italia. US research-market identity requiring an exact Italian medicine authorization record.
This page resolves Melanotan II to the US research-market identity tracked by Peptide Local. AIFA states that a medicinal product must have marketing authorization from AIFA or the European Commission before it can be marketed in Italy. The linked search and authorization records are verification routes, not a finding that every same-name offer is lawful or unlawful. No compound-specific Italian authorization record is attached here, so the exact product, presentation, seller, supply route, and intended claim remain unresolved.
This record resolves a name to the US laboratory research catalog tracked by Peptide Local. It does not establish authorization, lawful supply, medical use, or availability in the selected destination.
Guida italiana all'uso della banca dati AIFA e dell'elenco ministeriale delle farmacie online prima di confrontare un prodotto o un venditore collegato ai peptidi.
This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.
Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.
The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.
No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.
The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.
No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.
Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.
Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.
Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.